Murine Denys-Drash syndrome: evidence of podocyte de-differentiation and systemic mediation of glomerulosclerosis

被引:57
作者
Patek, CE
Fleming, S
Miles, CG
Bellamy, CO
Ladomery, M
Spraggon, L
Mullins, J
Hastie, ND
Hooper, ML
机构
[1] Western Gen Hosp, Mol Med Ctr, Sir Alastair Currie Canc Res UK Labs, Edinburgh EH4 2XU, Midlothian, Scotland
[2] Univ Dundee, Ninewells Hosp, Dept Pathol, Dundee DD1 9SY, Scotland
[3] Western Gen Hosp, MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland
[4] Univ Edinburgh, Sch Med, Div Pathol, Edinburgh EH8 9AG, Midlothian, Scotland
[5] Univ Edinburgh, Sch Med, Mol Physiol Lab, Edinburgh EH8 9AG, Midlothian, Scotland
关键词
D O I
10.1093/hmg/ddg240
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Denys-Drash syndrome (DDS) is caused by dominant mutations of the Wilms' tumour suppressor gene, WT1, and characterized by a nephropathy involving diffuse mesangial sclerosis, male pseudohermaphroditism and/or Wilms' tumourigenesis. Previously, we reported that heterozygosity for the Wt1(tmT396) mutation induces DDS in heterozygous and chimeric (Wt1(tmT396)/+ <----> +/+) mice. In the present study, the fate of Wt1 mutant cells in chimeric kidneys was assessed by in situ marker analysis, and immunocytochemistry was used to re-examine the claim that glomerulosclerosis (GS) is caused by loss of WT1 and persistent Pax-2 expression by podocytes. Wt1 mutant cells colonized glomeruli efficiently, including podocytes, but some sclerotic glomeruli contained no detectable Wt1 mutant cells. The development of GS was preceded by widespread loss of ZO-1 signal in podocytes (even in kidneys where <5% of glomeruli contained Wt1 mutant podocytes), increased intra-renal renin expression, and de novo podocyte TGF-beta1 expression, but not podocyte Pax-2 expression or loss of WT1, synaptopodin, alpha-actinin-4 or nephrin expression. However, podocytes in partially sclerotic glomeruli that still expressed WT1 at high levels showed reduced vimentin expression, cell cycle re-entry, and re-expressed desmin, cytokeratin and Pax-2. The results suggest that: (1) GS is not due to loss of WT1 expression by podocytes; (ii) podocyte Pax-2 expression reflects re-expression rather than persistent expression, and is the consequence of GS; (iii) GS is mediated systemically and the mechanism involves activation of the renin-angiotensin system; and (iv) podocytes undergo typical maturational changes but subsequently de-differentiate and revert to an immature phenotype during disease progression.
引用
收藏
页码:2379 / 2394
页数:16
相关论文
共 70 条
[1]  
ANSELL JD, 1991, DEVELOPMENT, V112, P489
[2]  
Bariéty J, 2001, J AM SOC NEPHROL, V12, P261, DOI 10.1681/ASN.V122261
[3]   Podocytes undergo phenotypic changes and express macrophagic-associated markers in idiopathic collapsing glomerulopathy [J].
Bariéty, J ;
Nochy, D ;
Mandet, C ;
Jacquot, C ;
Glotz, D ;
Meyrier, A .
KIDNEY INTERNATIONAL, 1998, 53 (04) :918-925
[4]  
Barisoni L, 1999, J AM SOC NEPHROL, V10, P51
[5]   Podocyte cell cycle regulation and proliferation in collapsing glomerulopathies [J].
Barisoni, L ;
Mokrzycki, M ;
Sablay, L ;
Nagata, M ;
Yamase, H ;
Mundel, P .
KIDNEY INTERNATIONAL, 2000, 58 (01) :137-143
[6]   HIV-1 induces renal epithelial dedifferentiation in a transgenic model of HIV-associated nephropathy [J].
Barisoni, L ;
Bruggeman, LA ;
Mundel, P ;
D'Agati, VD ;
Klotman, PE .
KIDNEY INTERNATIONAL, 2000, 58 (01) :173-181
[7]   Transforming growth factor-β in renal disease [J].
Bitzer, M ;
Sterzel, RB ;
Böttinger, EP .
KIDNEY & BLOOD PRESSURE RESEARCH, 1998, 21 (01) :1-12
[8]  
Breslow NE, 2000, CANCER RES, V60, P4030
[9]   Gonadal mosaicism of Frasier syndrome in 3 Chinese siblings with donor splice site mutation of Wilms' tumour gene [J].
Chak, WL ;
To, KF ;
Cheng, YL ;
Tsui, KM ;
Lo, KW ;
Tong, HM ;
Lai, FMM ;
Wong, FKM ;
Choi, KS ;
Chau, KF ;
Li, CS .
NEPHRON, 2002, 91 (03) :526-529
[10]   Expression of the Wilms' tumour gene WT1 in the developing human and in paediatric renal tumours: An immunohistochemical study [J].
Charles, AK ;
Mall, S ;
Watson, J ;
Berry, PJ .
JOURNAL OF CLINICAL PATHOLOGY-MOLECULAR PATHOLOGY, 1997, 50 (03) :138-144